Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)

Inclusion Criteria: * Normo-ovulatory patients * 18 - 38 included years old * BMI between 18 and 29 included kg/m² * Regular menstrual cycles * At least one healthy Fallopian tube * Normal uterus cavity * First treatment for IUI * Affiliation to the social security Exclusion Criteria: * Endometriosis Stage III * Total mobile sperm count \<1 million * Severe spermatogenesis disorders * Women with Poly Cystic Ovary Syndrom * History of OHSS or excessive response to gonadotrophins * Chronic disease with contraindication to ovarian stimulation with gonadotrophins * Known genetic disease * Hypothalamus or pituitary tumors * Ovarian hypertrophy or ovarian cyst not due to polycystic ovary syndrome * Gynecological bleeding of unknown etiology * Ovarian, uterine or breast carcinoma * Primary ovarian failure * Genital malformations incompatible with pregnancy * Uterine fibroids incompatible with pregnancy * Protected persons (pregnant women, nursing mothers, person under guardianship, minors, persons deprived of liberty, and persons unable to give consent) * Tumors (including meningioma) whose development is known or suspected to be progesterone-dependent * History of hepatic dysfunction * Have been receiving progestogen therapy for more than 6 months * Known contraindication to hormonal treatments (progestogens or oestrogens), or with a history of adverse events related to their use * Previous thromboembolism events during or following the use of gonadotrophins or with high risk factors for thromboembolic events (venous or arterial) * Previous or current treatment with gonadotrophins * Hypersensitivity to the active substance or to any of the excipients * High risk of OHSS such as women with AMH ≥ 35 pmol/L * History of severe uterine malformation (unicornuate or bicornuate uterus), * Past history of ovarian torsion * Uncontrolled thyroid dysfunction * Uncontrolled adrenal dysfunction * Hydrosalpynx * Breast pathologies not compatible with gonadotrophin stimulation * Use of infertility medications that could affect follicle stimulation and maturation such as GH * Participation in other interventional research * Not able to understand and sign the written informed consent form